A 12-month, prospective, randomized, single center, open label pilot study to evaluate the safety and efficacy of Myfortic in combination with tacrolimus and Thymoglobulin in early corticosteroid withdrawal

 
 
 
 

A 12-month, prospective, randomized, single center, open label pilot study to evaluate the safety and efficacy of Myfortic in combination with tacrolimus and Thymoglobulin in early corticosteroid withdrawal

Show simple item record


dc.contributor.advisor Succop, Paul en_US
dc.contributor.author WEIMERT, NICOLE A. en_US
dc.date.accessioned 2009-04-10T00:25:39Z
dc.date.available 2009-04-10T00:25:39Z
dc.date.created 2008 en_US
dc.date.issued 2009-04-10T00:25:39Z
dc.identifier.uri http://rave.ohiolink.edu/etdc/view?acc_num=ucin1211828943 en_US
dc.identifier.uri http://hdl.handle.net/2374.OX/105260
dc.description In 2005, greater than 16,000 kidney transplants were performed in the United States, with 68% of grafts functioning at 5 years (United Organ Sharing Network). Current immunosuppression regimens require long-term exposure to corticosteroids which are associated with an increased incidence of cardiovascular disease, obesity, and worsening diabetes control leading to early patient and graft loss. Combined with the increasing incidence of end-stage renal disease and subsequent need for transplantation, optimization of current immunosuppression is needed to ensure long-term patient and graft outcomes. Minimizing corticosteroids requires adequate exposure to mycophenolic acid to maintain the net level of immunosuppression needed to prevent rejection and graft loss. We will determine the pharmacokinetic profile of mycophenolic acid in a corticosteroid withdrawal protocol and will assess the pharmacodynamic relationship between inosine monophosphate dehydrogenase activity and mycophenolic acid inhibition peri-transplant based on the rate of acute rejection and incidence of adverse effects. en_US
dc.format application/pdf en_US
dc.format 54p. en_US
dc.rights unrestricted en_US
dc.rights Copyright and permissions information available at the source archive en_US
dc.subject mycophenolic acid en_US
dc.subject pharmacokinetic en_US
dc.subject kidney en_US
dc.subject transplant en_US
dc.title A 12-month, prospective, randomized, single center, open label pilot study to evaluate the safety and efficacy of Myfortic in combination with tacrolimus and Thymoglobulin in early corticosteroid withdrawal en_US
dc.type Electronic Thesis or Dissertation en_US
dc.degree.name MS en_US
dc.degree.level masters en_US
dc.degree.discipline Medicine : Epidemiology (Environmental Health) en_US
dc.degree.grantor University of Cincinnati en_US
dc.contributor.publisher University of Cincinnati / OhioLINK en_US

Files in this item

Files Size Format View

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record